Traumatic Brain Injury (TBI) is a common trauma and a worldwide major cause of mortality or disability in both civilian and military populations. TBI is not a pathological entity in its own, but rather a pattern of heterogeneous traumas with diverse and varied mechanisms and clinical expressions. Therefore, no universal medical response can be settled to it. Instead, medical management must be tailored to each individual's specific needs. If the current identification and prognosis of TBI is basically based on neurological examination and computerized tomography, specific biomarkers could represent a valuable aid in this diagnostic and therapeutic challenge. The potential implications of these markers are broad, encompassing among others the detection of unsuspected TBI, the monitoring of trauma severity, short-, intermediate- and long-term prognosis and apprehension of the extent of the sequelae. This topic has received broad and growing interest over the past decade, and the current literature is extensive. This short narrative review summarizes the latest advances in the field of plasma biomarkers in TBI patients.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!